Improving Market Access and Reimbursement for PGX Diagnostics | PGX for Pharmacists

ALVA10: the Power of Diagnostics Have you ever questioned why a payer pays for a medication, yet does not pay for the diagnostic test to determine if the medication will be efficacious and non-toxic for the patient? Or perhaps, you may have wondered why payers agree to pay for a medication for which no diagnostic test exists to diagnose the condition the medication treats? If these types of questions keep you awake at night like they do me, please join me for this podcast episode in which I and my esteemed colleagues, Hannah Mamuszka and Lena Chaihorsky of Alva10 discuss answers to these questions and the general state of the pharmacogenomics market access and reimbursement landscape. Lena Chaihorsky & Hannah Mamuszka join Dr. Becky Winslow to discuss diagnostic testing and the preventative savings for PGX testing for patients on multiple medications. Episode Based on LI article written by Hannah: https://www.linkedin.com/pulse/bigger-problem-aduhelm-we-dont-know-who-has-disease-hannah-mamuszka/?trackingId=GIb%2BLnNCys35sG19%2Fo0NFw%3D%3D ALVA10: https://alva10dx.com/ See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices